L. Amiot, M. Onno, B. Drénou, C. Monvoisin, and R. Fauchet, HLA-G class I gene expression in normal and malignant hematopoietic cells, Human Immunology, vol.59, issue.8, pp.524-528, 1998.
DOI : 10.1016/S0198-8859(98)00041-X

T. Avril, M. De-tayrac, C. Leberre, and V. Quillien, Not All Polyriboinosinic-polyribocytidylic Acids (Poly I:C) are Equivalent for Inducing Maturation of Dendritic Cells, Journal of Immunotherapy, vol.32, issue.4, pp.353-362, 2009.
DOI : 10.1097/CJI.0b013e31819d29bf

URL : https://hal.archives-ouvertes.fr/inserm-00373586

D. Bainbridge, S. Ellis, L. Bouteiller, P. Sargent, and I. , HLA-G remains a mystery, Trends in Immunology, vol.22, issue.10, pp.548-552, 2001.
DOI : 10.1016/S1471-4906(01)02031-2

R. Berger, R. Rotem-yehudar, G. Slama, S. Landes, A. Kneller et al., Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies, Clinical Cancer Research, vol.14, issue.10, pp.3044-3051, 2008.
DOI : 10.1158/1078-0432.CCR-07-4079

R. Brahmer, S. L. Topalian, J. Powderly, I. Wollner, J. Picus et al., Phase II experience with MDX-1106 (Ono-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies, 2009.

E. D. Carosella, B. Favier, N. Rouas-freiss, P. Moreau, and J. Lemaoult, Beyond the increasing complexity of the immunomodulatory HLA-G molecule, Blood, vol.111, issue.10, pp.4862-4870, 2008.
DOI : 10.1182/blood-2007-12-127662

A. Chahlavi, P. Rayman, A. L. Richmond, K. Biswas, R. Zhang et al., Glioblastomas Induce T-Lymphocyte Death by Two Distinct Pathways Involving Gangliosides and CD70, Cancer Research, vol.65, issue.12, pp.5428-5438, 2005.
DOI : 10.1158/0008-5472.CAN-04-4395

C. C. Chang and S. Ferrone, HLA-G in melanoma: can the current controversies be solved?, Seminars in Cancer Biology, vol.13, issue.5, pp.361-369, 2003.
DOI : 10.1016/S1044-579X(03)00027-0

D. B. Constam, J. Philipp, U. V. Malipiero, P. Ten-dijke, M. Schachner et al., Differential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia, J. Immunol, vol.148, pp.1404-1410, 1992.

S. Corm, C. Berthon, M. Imbenotte, V. Biggio, M. Lhermitte et al., Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients??? sera by HPLC and is inducible by IFN-??, Leukemia Research, vol.33, issue.3, pp.490-494, 2009.
DOI : 10.1016/j.leukres.2008.06.014

B. Davies, S. Hiby, L. Gardner, Y. W. Loke, and A. King, HLA-G Expression by Tumors, American Journal of Reproductive Immunology, vol.45, issue.2, 2001.
DOI : 10.1111/j.8755-8920.2001.450207.x

H. Dong, S. E. Strome, D. R. Salomao, H. Tamura, F. Hirano et al., Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion, Nat. Med, vol.8, pp.793-800, 2002.

H. Okada, Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses, Cancer Res, vol.66, pp.5883-5891, 2006.

G. Eisele, J. Wischhusen, M. Mittelbronn, R. Meyermann, I. Waldhauer et al., TGF-?? and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells, Brain, vol.129, issue.9, pp.2416-2425, 2006.
DOI : 10.1093/brain/awl205

M. R. Bowman, B. M. Carreno, M. Collins, C. R. Wood, and T. Honjo, Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation, J. Exp. Med, vol.192, pp.1027-1034, 2000.

L. Gorelik and R. A. Flavell, Transforming growth factor-beta in T-cell biology, Nat. Rev, 2002.

R. Grant and V. Kapoor, Inhibition of indoleamine 2,3-dioxygenase activity in IFN-?? stimulated astroglioma cells decreases intracellular NAD levels, Biochemical Pharmacology, vol.66, issue.6, pp.1033-1036, 2003.
DOI : 10.1016/S0006-2952(03)00464-7

C. Gratas, Y. Tohma, E. G. Van-meir, M. Klein, M. Tenan et al., Fas Ligand Expression in Glioblastoma Cell Lines and Primary Astrocytic Brain Tumors, Brain Pathology, vol.94, issue.3, pp.863-869, 1997.
DOI : 10.1093/intimm/6.10.1567

R. J. Greenwald, G. J. Freeman, and A. H. Sharpe, THE B7 FAMILY REVISITED, Annual Review of Immunology, vol.23, issue.1, pp.515-548, 2005.
DOI : 10.1146/annurev.immunol.23.021704.115611

J. B. Katz, A. J. Muller, and G. C. Prendergast, Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape, Immunological Reviews, vol.176, issue.1, pp.206-221, 2008.
DOI : 10.1093/carcin/16.2.399

S. Kovats, E. K. Main, C. Librach, M. Stubblebine, S. J. Fisher et al., A class I antigen, HLA-G, expressed in human trophoblasts, Science, vol.248, issue.4952, pp.220-223, 1990.
DOI : 10.1126/science.2326636

J. Leitlein, S. Aulwurm, R. Waltereit, U. Naumann, B. Wagenknecht et al., Processing of Immunosuppressive Pro-TGF-??1,2 by Human Glioblastoma Cells Involves Cytoplasmic and Secreted Furin-Like Proteases, The Journal of Immunology, vol.166, issue.12, pp.7238-7243, 2001.
DOI : 10.4049/jimmunol.166.12.7238

L. M. Liau, R. M. Prins, S. M. Kiertscher, S. K. Odesa, T. J. Kremen et al., Dendritic Cell Vaccination in Glioblastoma Patients Induces Systemic and Intracranial T-cell Responses Modulated by the Local Central Nervous System Tumor Microenvironment, Clinical Cancer Research, vol.11, issue.15, pp.5515-5525, 2005.
DOI : 10.1158/1078-0432.CCR-05-0464

T. Miyazaki, K. Moritake, K. Yamada, N. Hara, H. Osago et al., Indoleamine 2,3-dioxygenase as a new target for malignant glioma therapy, Journal of Neurosurgery, vol.111, issue.2, 2009.
DOI : 10.3171/2008.10.JNS081141

D. H. Munn and A. L. Mellor, Indoleamine 2,3-dioxygenase and tumor-induced tolerance, Journal of Clinical Investigation, vol.117, issue.5, 2007.
DOI : 10.1172/JCI31178

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1857253

A. L. Mellor, Prevention of allogeneic fetal rejection by tryptophan catabolism, Science, vol.281, pp.1191-1193, 1998.

S. Nagata and P. Golstein, The Fas death factor, Science, vol.267, issue.5203, pp.1449-1456, 1995.
DOI : 10.1126/science.7533326

T. Nitta, M. Ebato, K. Sato, and K. Okumura, Expression of tumour necrosis factor-alpha, beta and interferon-gamma genes within human neuroglial tumour cells and brain specimens, 1994.

F. Okano, W. J. Storkus, W. H. Chambers, I. F. Pollack, and H. Okada, Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain, Clin. Cancer Res, vol.8, pp.2851-2855, 2002.

B. Pasche, Role of transforming growth factor beta in cancer, Journal of Cellular Physiology, vol.25, issue.18, pp.153-168, 2001.
DOI : 10.1002/1097-4652(200002)186:2<153::AID-JCP1016>3.0.CO;2-J

B. Popko, J. G. Corbin, K. D. Baerwald, J. Dupree, and A. M. Garcia, The effects of interferon-?? on the central nervous system, Molecular Neurobiology, vol.8, issue.1-2, pp.19-35, 1997.
DOI : 10.1007/BF02740619

J. Matsuzaki, D. Valmori, M. Ayyoub, P. J. Frederick, A. Beck et al., Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of Tcell proliferation in human epithelial ovarian cancer, Cancer Res, vol.69, pp.5498-5504, 2009.

E. G. Meir, N. De-tribolet, J. Tschopp, and P. Y. Dietrich, Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?, J. Clin. Invest, vol.99, pp.1173-1178, 1997.

H. H. Soliman, S. Antonia, D. Sullivan, N. Vanahanian, C. Link et al., Overcoming tumor antigen anergy in human malignancies using the novel indeolamine 2,3-dioxygenase (IDO) enzyme inhibitor, 1-methyl-D-tryptophan (1MT), J. Clin. Oncol (Meeting Abstracts, vol.27, p.3004, 2009.

R. J. Strege, C. Godt, A. M. Stark, H. H. Hugo, and H. M. Mehdorn, Protein Expression of Fas, Fas Ligand, Bcl-2 and TGF??2 and Correlation with Survival in Initial and Recurrent Human Gliomas, Journal of Neuro-Oncology, vol.67, issue.1/2, pp.29-39, 2004.
DOI : 10.1023/B:NEON.0000021739.34343.75

D. Lacombe, J. G. Cairncross, and R. O. Mirimanoff, European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial, Lancet Oncol, vol.10, pp.459-466, 2009.

Y. Suzuki, J. Claflin, X. Wang, A. Lengi, and T. Kikuchi, Microglia and macrophages as innate producers of interferon-gamma in the brain following infection with Toxoplasma gondii, International Journal for Parasitology, vol.35, issue.1, pp.83-90, 2004.
DOI : 10.1016/j.ijpara.2004.10.020

A. Taylor, Review of the activation of TGF-?? in immunity, Journal of Leukocyte Biology, vol.85, issue.1, pp.29-33, 2009.
DOI : 10.1189/jlb.0708415

M. D. Galibert and J. Mosser, Integrative genome-wide analysis reveals a robust genomic glioblastoma signature associated with copy number driving changes in gene expression, 2009.
URL : https://hal.archives-ouvertes.fr/inserm-00352960

D. A. Thomas and J. Massagué, TGF-?? directly targets cytotoxic T cell functions during tumor evasion of immune surveillance, Cancer Cell, vol.8, issue.5, pp.369-380, 2005.
DOI : 10.1016/j.ccr.2005.10.012

B. J. Eynde, Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase, Nat. Med, vol.9, pp.1269-1274, 2003.

P. R. Walker, T. Calzascia, and P. Y. Dietrich, All in the head: obstacles for immune rejection of brain tumours, Immunology, vol.21, issue.1, pp.28-38, 2002.
DOI : 10.1016/S1471-4906(01)02031-2

P. R. Walker, P. Saas, and P. Y. Dietrich, Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back, J. Immunol, vol.158, pp.4521-4524, 1997.

M. Weller and A. Fontana, The failure of current immunotherapy for malignant glioma, 1995.

B. Widner, E. R. Werner, H. Schennach, H. Wachter, and D. Fuchs, Simultaneous measurement of serum tryptophan and kynurenine by HPLC, Clin. Chem, vol.43, pp.2424-2426, 1997.

E. H. Weiss, A. Melms, and M. Weller, A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape, J. Immunol, vol.168, pp.4772-4780, 2002.

R. Wilmotte, K. Burkhardt, V. Kindler, M. C. Belkouch, G. Dussex et al., B7-homolog 1 expression by human glioma: a new mechanism of immune evasion, NeuroReport, vol.16, issue.10, pp.1081-1085, 2005.
DOI : 10.1097/00001756-200507130-00010

S. Wintterle, B. Schreiner, M. Mitsdoerffer, D. Schneider, L. Chen et al., Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis, Cancer Res, vol.63, pp.7462-7467, 2003.

R. Yamanaka, Cell- and peptide-based immunotherapeutic approaches for glioma, Trends in Molecular Medicine, vol.14, issue.5, 2008.
DOI : 10.1016/j.molmed.2008.03.003

M. Takahashi and R. Tanaka, Vaccination of recurrent glioma patients with tumour lysatepulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial, Br. J. Cancer, vol.89, pp.1172-1179, 2003.

R. Yamanaka, J. Homma, N. Yajima, N. Tsuchiya, M. Sano et al., Clinical Evaluation of Dendritic Cell Vaccination for Patients with Recurrent Glioma: Results of a Clinical Phase I/II Trial, Clinical Cancer Research, vol.11, issue.11, pp.4160-4167, 2005.
DOI : 10.1158/1078-0432.CCR-05-0120

J. S. Yu, G. Liu, H. Ying, W. H. Yong, K. L. Black et al., Vaccination with Tumor Lysate-Pulsed Dendritic Cells Elicits Antigen-Specific, Cytotoxic T-Cells in Patients with Malignant Glioma, Cancer Research, vol.64, issue.14, pp.4973-4979, 2004.
DOI : 10.1158/0008-5472.CAN-03-3505

B. Minev, C. Delgado, H. T. Wepsic, H. Okada, and M. R. Jadus, Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics, Clin. Cancer Res, vol.13, pp.566-575, 2007.

L. Amiot and V. , ACKNOWLEDGMENTS We thank persons and organizations which have contributed to this work: Stéphane Moiteaux for his excellent technical assistance Catros and A. Clavreul for their kind gifts of the JEG-3 trophoblastic cell line, U251 and U87MG cell lines, respectively; the Biogenouest® transcriptomic platform from Rennes for the microarray analysis; Alain Feutrel and Pascale Bellaud from the Biogenouest® histopathology platform (IFR 140